ArticleEnvironmental science and pollution research international2018
Inactivation of influenza A virus via exposure to silver nanoparticle-decorated silica hybrid composites.
Article in Environmental science and pollution research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 51 citations in OpenAlex.
- Silver Nanoparticles: A Versatile Tool Against Infectious and Non-Infectious Diseases.Antibiotics (Basel, Switzerland) · 2025Review
- Nanostructures for prevention, diagnosis, and treatment of viral respiratory infections: from influenza virus to SARS-CoV-2 variants.Journal of nanobiotechnology · 2023Review
- Silver Nanoparticles: Review of Antiviral Properties, Mechanism of Action and Applications.Microorganisms · 2023Review
- Role of bioaerosol in virus transmission and material-based countermeasures.Exploration (Beijing, China) · 2022Review
- Passive antifouling and active self-disinfecting antiviral surfaces.Chemical engineering journal (Lausanne, Switzerland : 1996) · 2022Review
- Article
- Synthesis approach-dependent antiviral properties of silver nanoparticles and nanocomposites.Journal of nanostructure in chemistry · 2022Review
- Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19.Frontiers in cellular and infection microbiology · 2022Review
- Past and Current Progress in the Development of Antiviral/Antimicrobial Polymer Coating towards COVID-19 Prevention: A Review.Polymers · 2021Review
- Silver Nanoparticles as Potential Antiviral Agents.Pharmaceutics · 2021Review
- From outbreak of COVID-19 to launching of vaccination drive: invigorating single-use plastics, mitigation strategies, and way forward.Environmental science and pollution research international · 2021Review
- Silver nanoparticles as a potential treatment against SARS-CoV-2: A review.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Silver nanoparticle based multifunctional approach for combating COVID-19.Sensors international · 2021Article
- How can nanotechnology help to combat COVID-19? Opportunities and urgent need.Journal of nanobiotechnology · 2020Review
- Review
- Biogenic Silver Nanoparticles Can ControlFrontiers in microbiology · 2020Article
- Self-Therapeutic Nanomaterials: Applications in Biology and Medicine.Materials today (Kidlington, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Influenza A virus (IFV-A) is one of the main cause of seasonal flu and can infect various of host species via the reassortment of segmented RNA genomes. Silver nanoparticles (AgNPs) have been known as excellent antiviral agent against IFV. However, the use of free AgNPs has several major drawbacks, including the inherent aggregation among AgNPs and unwanted cytotoxic or genotoxic damages for human body via inhalation or ingestion. In this study, we assessed the efficacy of our novel ~ 30-nm-diameter AgNP-decorated silica hybrid composite (Ag30-SiO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.